Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases

Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases is a phase 2, randomised interventional study registered as NCT06683703 by Beijing Biostar Pharmaceuticals Co., Ltd., with a registry enrolment figure of 118 participants, started 2024-12-01 and due to reach its primary completion in 2026-12-01. Interventions recorded: Utidelone combined with Bevacizumab; Utidelone; Utidelone combined with Bevacizumab; Utidelone combined with Bevacizumab. Conditions listed: Non-small Cell Lung Cancer Patients with Brain Metastases. Primary outcome: Intracranial objective response rate (iORR) according to the RECIST 1.1.; Determining the Expansion Dose. Lung eligibility wording from the registry: "non-squamous non-small cell lung cancer (adenocarcinoma or adenocarcinoma component dominant) with brain parenchymal metastasis confirmed by histology or cytology, but unsuitable or refused local treatment/surgery;". No results are recorded here; the registry entry is the source.